Dr. Mindy L. Simpson, M.D.
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
1653 W Congress Pkwy, 1591 Jelke
Chicago, IL 60612
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2006
Licensed in Illinois since 2005, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
IL license 036-114998 (first issued 2005; active) -
Pediatrics Physician
IL license 036-114998 (first issued 2005; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 9 companies reported 54 payments worth $76,438 in total to this clinician.
| Csl Behring | $37,739 |
|---|---|
| Genzyme Corporation | $28,771 |
| Pfizer Inc. | $6,195 |
| BioMarin Pharmaceutical Inc. | $1,900 |
| Bayer HealthCare Pharmaceuticals Inc. | $1,607 |
| Octapharma USA, Inc. | $90.63 |
| Novo Nordisk Inc | $55.95 |
| Hema Biologics, LLC | $48.96 |
| Consulting Fee | $27,347 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $26,843 |
| Travel and Lodging | $21,000 |
| Food and Beverage | $1,248 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Csl Behring Dec 1, 2025 | Travel and Lodging Idelvion · Hematology · travel to Sydney, Australia | $16,167 |
| Genzyme Corporation Apr 8, 2025 | Compensation for services other than consulting (speaking, faculty) | $11,184 |
| Genzyme Corporation Nov 7, 2025 | Consulting Fee QFITLIA | $10,101 |
| Csl Behring May 20, 2025 | Consulting Fee Idelvion; HEMGENIX · Hematology | $7,728 |
| Pfizer Inc. Oct 2, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $6,050 |
| Genzyme Corporation Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,592 |
| Csl Behring Dec 1, 2025 | Compensation for services other than consulting (speaking, faculty) Idelvion · Hematology | $5,152 |
| BioMarin Pharmaceutical Inc. Mar 6, 2025 | Consulting Fee ROCTAVIAN · Hemophilia A | $1,900 |
| Bayer HealthCare Pharmaceuticals Inc. Jun 24, 2025 | Consulting Fee Jivi · Hematology | $1,568 |
| Csl Behring Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) Idelvion · Hematology · in-kind | $1,482 |
All 34 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Csl Behring Dec 1, 2025 | Travel and Lodging Idelvion · Hematology · travel to Sydney, Australia | $16,167 |
| Csl Behring Dec 1, 2025 | Compensation for services other than consulting (speaking, faculty) Idelvion · Hematology | $5,152 |
| Genzyme Corporation Nov 7, 2025 | Consulting Fee QFITLIA | $10,101 |
| Genzyme Corporation Nov 7, 2025 | Travel and Lodging QFITLIA · travel to Dallas, TX · in-kind | $347 |
| Genzyme Corporation Nov 7, 2025 | Travel and Lodging QFITLIA · travel to Dallas, TX · in-kind | $297 |
| Genzyme Corporation Nov 7, 2025 | Travel and Lodging QFITLIA · travel to Dallas, TX · in-kind | $246 |
| Genzyme Corporation Nov 7, 2025 | Travel and Lodging QFITLIA · travel to Dallas, TX | $49.00 |
| Csl Behring Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) Idelvion · Hematology · in-kind | $508 |
| Csl Behring Oct 17, 2025 | Travel and Lodging Idelvion · Hematology · travel to Brisbane, Australia · in-kind | $139 |
| Csl Behring Oct 16, 2025 | Travel and Lodging Idelvion · Hematology · travel to Sydney, Australia · in-kind | $1,091 |
| Csl Behring Oct 16, 2025 | Travel and Lodging Idelvion · Hematology · travel to Sydney, Australia · in-kind | $90.30 |
| Csl Behring Oct 15, 2025 | Travel and Lodging Idelvion · Hematology · travel to Brisbane, Australia · in-kind | $386 |
| Csl Behring Oct 15, 2025 | Travel and Lodging Idelvion · Hematology · travel to Melbourne, Australia · in-kind | $94.45 |
| Csl Behring Oct 14, 2025 | Travel and Lodging Idelvion · Hematology · travel to Melbourne, Australia · in-kind | $36.82 |
| Csl Behring Oct 14, 2025 | Travel and Lodging Idelvion · Hematology · travel to Melbourne, Australia · in-kind | $27.04 |
| Csl Behring Oct 14, 2025 | Travel and Lodging Idelvion · Hematology · travel to Melbourne, Australia · in-kind | $20.98 |
| Csl Behring Oct 13, 2025 | Travel and Lodging Idelvion · Hematology · travel to Melbourne, Australia · in-kind | $296 |
| Csl Behring Oct 13, 2025 | Travel and Lodging Idelvion · Hematology · travel to Melbourne, Australia · in-kind | $269 |
| Pfizer Inc. Oct 2, 2025 | Consulting Fee HYMPAVZI · IMMUNOLOGY | $6,050 |
| Pfizer Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) HYMPAVZI · IMMUNOLOGY | $124 |
| Csl Behring Jul 25, 2025 | Compensation for services other than consulting (speaking, faculty) Idelvion · Hematology · in-kind | $296 |
| Bayer HealthCare Pharmaceuticals Inc. Jun 24, 2025 | Consulting Fee Jivi · Hematology | $1,568 |
| Genzyme Corporation Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,592 |
| Csl Behring Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) Idelvion · Hematology · in-kind | $1,482 |
| Csl Behring May 20, 2025 | Consulting Fee Idelvion; HEMGENIX · Hematology | $7,728 |
| Csl Behring May 20, 2025 | Travel and Lodging Idelvion; HEMGENIX · Hematology · travel to Miami, FL | $79.00 |
| Csl Behring May 2, 2025 | Travel and Lodging Idelvion; HEMGENIX · Hematology · travel to Miami, FL · in-kind | $462 |
| Csl Behring May 2, 2025 | Travel and Lodging HEMGENIX; Idelvion · Hematology · travel to Miami, FL · in-kind | $328 |
| Genzyme Corporation Apr 8, 2025 | Compensation for services other than consulting (speaking, faculty) | $11,184 |
| Genzyme Corporation Apr 8, 2025 | Travel and Lodging travel to Lake Buena Vista, FL | $383 |
| Genzyme Corporation Apr 8, 2025 | Travel and Lodging travel to Lake Buena Vista, FL | $191 |
| Csl Behring Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) Idelvion · Hematology · in-kind | $1,337 |
| Csl Behring Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) Idelvion · Hematology · in-kind | $1,169 |
| BioMarin Pharmaceutical Inc. Mar 6, 2025 | Consulting Fee ROCTAVIAN · Hemophilia A | $1,900 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $37,358 in research payments for these studies, mostly to the institutions running them.
- A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05568459 - Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
Sanofi US Services Inc. · Active, not recruiting · NCT04644575
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.